

Agenda for February 2026

Pharmacology and Therapeutics advisory committee (PTAC) meeting

19 December 2025

Information on what the Pharmacology and Therapeutics Advisory Committee (PTAC) will be considering at its upcoming meeting on 12 and 13 February 2026.

Applications

Aprepitant 40 mg for people at high risk of post-operative nausea and vomiting (PONV)

The Committee will discuss an application for aprepitant 40 mg for people at high risk of post-operative nausea and vomiting (PONV).

[Application for Aprepitant 40 mg for PONV](#)

Abemaciclib (branded as Verzenio) for the treatment of people with hormone receptor positive, HER2 negative metastatic breast cancer

The Committee will discuss an application for abemaciclib for the treatment of HR positive, HER2 negative metastatic breast cancer.

[Application for Abemaciclib for metastatic breast cancer](#)

Multiple applications for PD-1 inhibitors for the treatment of people with malignant pleural mesothelioma

The Committee will re-look at applications for pembrolizumab (Keytruda) (with pemetrexed and chemotherapy) and nivolumab & Ipilimumab (Opdivo, Yervoy) for the treatment of people malignant

pleural mesothelioma to consider the recommendations relevant to each other.

- pembrolizumab (with pemetrexed and chemotherapy) with all histological subtypes of malignant pleural mesothelioma, unresectable advanced, in the 1st line.

[Application for pembrolizumab \(with pemetrexed and chemotherapy\) \(KEYTRUDA\) for malignant pleural mesothelioma](#)

- pembrolizumab (with pemetrexed and chemotherapy) for the treatment of non-epithelioid histological subtypes of malignant pleural mesothelioma, unresectable advanced, in the 1st line.

[Application for pembrolizumab \(with pemetrexed and chemotherapy\) \(KEYTRUDA\) for malignant pleural mesothelioma](#)

- nivolumab & ipilimumab (Opdivo, Yervoy) for unresectable, malignant, mesothelioma.

[Application for Nivolumab Ipilimumab for unresectable, malignant, mesothelioma](#)

- nivolumab & ipilimumab (Opdivo, Yervoy) for unresectable, malignant, mesothelioma (sarcomatoid or biphasic subtypes).

[Application for Nivolumab Ipilimumab for unresectable, malignant, mesothelioma \(sarcomatoid or biphasic subtypes\)](#)

Testosterone cream (branded as AndroFeme 1) for Hypoactive sexual desire dysfunction (HSDD) in postmenopausal women

The Committee will consider new information and review previous recommendations for testosterone cream (AndroFeme 1) for the treatment of hypoactive sexual desire dysfunction (HSDD) in postmenopausal women.

[Application for testosterone cream \(AndroFeme 1\) for the treatment of HSDD](#)

International Normalized Ratio (INR) point-of-care meters and test strips (branded as Roche CoaguChek® XS system) for people using warfarin who have rheumatic heart disease and a mechanical heart valve

The Committee will review an application for International Normalized Ratio (INR) point-of-care coagulometers and test strips for people using warfarin as long-term anticoagulation management who have rheumatic heart disease and a mechanical heart valve.

[Application for INR point-of-care coagulometers and test strips for rheumatic heart disease](#)

Salbutamol dry powder inhaler (branded as ventolin accuhaler) for COPD and asthma

The Committee will review an application for salbutamol dry powder inhaler for the treatment of Chronic Obstructive Pulmonary Disease (COPD) and asthma.

[Application for salbutamol dry powder inhaler for COPD and asthma](#)

Whey Protein Concentrate (Unflavoured, McLeod Nutrition) as a protein supplement

The Committee will review an application for whey Protein Concentrate (Unflavoured) as a protein supplement for protein losing enteropathy, high protein needs, or use as a component in a modular formula.

[Application for Whey Protein Concentrate \(Unflavoured\) as a protein supplement](#)

Plant based oral nutrition (branded as Fortisip PlantBased) for people who need nutrition support

The Committee will review an application for a plant based oral feed as an option for people needing oral nutrition support.

[Application for Fortisip PlantBased \(branded as Fortisip PlantBased\) for oral nutrition support](#)

Tadalafil (branded as Cialis, Adcirca) for the treatment of people with pulmonary arterial hypertension, Raynards syndrome or undergoing cardiac surgery.

The Committee will review applications for tadalafil for pulmonary arterial hypertension (PAH), Raynards syndrome and people undergoing cardiac surgery.

[Application for tadalafil \(Cialis, Adcirca\) for PAH](#)

[Application for tadalafil \(Cialis, Adcirca\) for PAH in peri operative use in patients, undergoing cardiac surgery](#)

Sodium chloride oral liquid 2mmol/mL (branded as Biomed) for use in babies and children as a sodium supplement

The Committee will review an application for sodium chloride oral liquid 2mmol/mL as a sodium replacement for neonates and children

[Application for sodium chloride oral liquid 2mmol/mL \(branded as Biomed\) as sodium replacement](#)

Advisory meeting agenda setting

The scheduling and agenda setting process for advisory meetings considers multiple factors. We aim to balance the relative priorities of clinical advice needed across indications, the factors for consideration for each application (for example unmet health need), the time since applications were received and the internal and advisor resource available to support each meeting.